Clinicopathological impact of CD20 expression in childhood B cell precursor acute lymphoblastic leukemia (BCP-ALL)
Authors:
- 1 May 2017
- journal article
- research article
- Published by Springer Nature in Comparative Clinical Pathology
- Vol. 26 (4) , 943-949
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- CD20 and Outcome of Childhood Precursor B-cell Acute Lymphoblastic LeukemiaJournal of Pediatric Hematology/Oncology, 2015
- How I treat Philadelphia chromosome–positive acute lymphoblastic leukemiaBlood, 2010
- Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trialThe Lancet Oncology, 2010
- Acute Lymphoblastic Leukemia in Adolescents and Young AdultsHematology/Oncology Clinics of North America, 2009
- Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemiaBlood, 2009
- CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapyBlood, 2008
- Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both GlobalCD20Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional LevelsClinical Cancer Research, 2008
- Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)Blood, 2007
- Development of Rituximab-Resistant Lymphoma Clones with Altered Cell Signaling and Cross-Resistance to ChemotherapyCancer Research, 2007
- Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospectsAnnals of Hematology, 2003